Individualizing Insulin Therapy in the Management of Type 2 Diabetes

被引:14
|
作者
Moghissi, Etie [1 ]
King, Allen B. [2 ]
机构
[1] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA
[2] CA Diabet Care Ctr, Salinas, CA USA
关键词
Diabetes management; Glycemic target; Individualizing therapy; Insulin; Type; 2; diabetes; TO-TARGET TRIAL; GLYCEMIC CONTROL; PARALLEL-GROUP; NPH INSULIN; OPEN-LABEL; GLUCOSE CONTROL; DETEMIR; MELLITUS; EXENATIDE; ALGORITHM;
D O I
10.1016/j.amjmed.2014.07.002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
It is recognized that reducing hyperglycemia early on in disease progression has long-term benefits for patients with diabetes. Insulin therapy has greater potential to reduce hyperglycemia than other therapies; however, there is often a significant delay in insulin initiation and intensification. Insulin replacement therapy in type 2 diabetes should no longer be viewed as the treatment of last resort. With the development of modern insulin analogs, the field has evolved. Large clinical trials have improved our understanding of the potential benefits and risks associated with intensive glycemic control in different patient populations and highlighted the need for individualization of glycemic targets and treatment strategies. Current treatment guidelines recognize the important role of insulin therapy both early on and throughout the progression of type 2 diabetes. (C) 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码:S3 / S10
页数:8
相关论文
共 50 条
  • [31] Current State and Principles of Basal Insulin Therapy in Type 2 Diabetes
    Vargas-Uricoechea, Hernando
    JOURNAL OF CLINICAL MEDICINE RESEARCH-CANADA, 2022, 14 (01): : 8 - 21
  • [32] Pharmacologic Therapy of Type 2 Diabetes
    Wright, Jennifer J.
    Tylee, Tracy S.
    MEDICAL CLINICS OF NORTH AMERICA, 2016, 100 (04) : 647 - +
  • [33] Insulin process in Type 2 Diabetes Mellitus Therapy
    Cosmi, Franco
    D'Orazio, Simona
    Mariottoni, Beatrice
    Tarquini, Barbara
    Cosmi, Deborah
    GIORNALE ITALIANO DI CARDIOLOGIA, 2022, 23 (01) : 52 - 62
  • [34] Risk of hypoglycemia in youth with type 2 diabetes on insulin
    Shahid, Madhia
    Shaibi, Gabriel Q.
    Baines, Hayley
    Garcia-Filion, Pamela
    Gonzalez-Garcia, Zoe
    Olson, Micah
    JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2018, 31 (06) : 625 - 630
  • [35] Individualizing Dual Therapy for Type 2 Diabetes Mellitus
    Skolnik, Neil S.
    Jaffa, Florence
    Kiriakov, Yan
    JOURNAL OF FAMILY PRACTICE, 2017, 66 (04) : S4 - S9
  • [36] The changing landscape of automated insulin delivery in the management of type 1 diabetes
    Lakshman, Rama
    Boughton, Charlotte
    Hovorka, Roman
    ENDOCRINE CONNECTIONS, 2023, 12 (08)
  • [37] Type 2 Diabetes Mellitus: Outpatient Insulin Management
    Howard-Thompson, Amanda
    Khan, Muneeza
    Jones, Morgan
    George, Christa M.
    AMERICAN FAMILY PHYSICIAN, 2018, 97 (01) : 29 - 37
  • [38] Use of basal insulin in the management of adults with type 2 diabetes: An Asia-Pacific evidence-based clinical practice guideline
    Ji, Linong
    Luo, Yingying
    Bee, Yong Mong
    Xia, Jun
    Nguyen, Khue Thy
    Zhao, Weigang
    Chen, Liming
    Chan, Siew Pheng
    Deerochanawong, Chaicharn
    Lim, Soo
    Yabe, Daisuke
    McGill, Margaret
    Suastika, Ketut
    Li, Xiaoying
    Kong, Alice Pik Shan
    Chen, Wei
    Zhao, Zhan
    Xu, Chenchen
    Deodat, Marisa
    Yao, Xiaomei
    JOURNAL OF DIABETES, 2023, 15 (06) : 474 - 487
  • [39] Therapy in type 2 diabetes: Insulin glargine vs. 2 NPH insulin both in combination with glimepiride
    Eliaschewitz, FG
    Calvo, C
    Valbuena, H
    Ruiz, M
    Aschner, P
    Villena, J
    Ramirez, LA
    Jimenez, J
    ARCHIVES OF MEDICAL RESEARCH, 2006, 37 (04) : 495 - 501
  • [40] Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes
    Levin, Philip
    Wei, Wenhui
    Wang, Li
    Pan, Chunshen
    Douglas, Damon
    Baser, Onur
    CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (03) : 439 - 446